Immunopathological study of mesonephric lesions of cervix uteri and vagina

A Kondi-Pafitis1, E Kairi, K I Kontogianni

  • 1Pathology Laboratory and 2nd Clinic of Obstetrics and Gynecology, Areteion University Hospital, Athens Medical School Athens, Greece.

Insights

This study differentiates mesonephric cervical lesions from normal cervical tissues using specific markers. Identifying these unique immunopathological characteristics aids in accurate diagnosis and treatment of mesonephric cervical carcinoma.

Area of Science:

  • Gynecologic Pathology
  • Histopathology
  • Immunohistochemistry

Background:

  • Mesonephric lesions in the female genital tract can be challenging to distinguish from other glandular lesions.
  • Accurate identification is crucial for appropriate clinical management and treatment.

Purpose of the Study:

  • To investigate the histochemical and immunohistochemical profiles of mesonephric cervical remnants, mesonephric cervical carcinoma, and vaginal Gardner cysts.
  • To identify specific markers that differentiate mesonephric lesions from endocervical glandular lesions.

Main Methods:

  • Histochemical staining for mucin, proteoglycans, and glycogen.
  • Immunohistochemical analysis for Carcinoembryonic Antigen (CEA), cytokeratins, secretory component, and vimentin.
  • Comparative analysis of 17 mesonephric cervical remnants, 4 mesonephric cervical carcinomas, and 9 vaginal Gardner cysts.

Main Results:

  • Mesonephric lesions were consistently negative for mucin, glycogen, CEA, and secretory component.
  • Mesonephric lesions demonstrated positivity for vimentin and broad-spectrum cytokeratins.
  • Distinct immunopathological characteristics were observed in mesonephric carcinomas.

Conclusions:

  • Immunohistochemistry is valuable in distinguishing mesonephric cervical lesions from endocervical lesions.
  • Specific markers like vimentin and cytokeratins aid in the identification of mesonephric lesions.
  • Understanding these immunopathological features facilitates the diagnosis and targeted treatment of mesonephric cervical carcinoma.